Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma
July 29 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:
CALIDI BIOTHERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR CLD-201 (SUPERNOVA), A FIRST-IN-CLASS STEM-CELL LOADED VIRAL THERAPY FOR THE TREATMENT OF PATIENTS WITH SOFT TISSUE SARCOMA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.